Kenton Stewart
Sales & Marketing bei UROVANT SCIENCES LTD.
Profil
Kenton Stewart is a professional who has worked in the pharmaceutical industry for over a decade.
He is currently a Senior Vice President-Market Access at Urovant Sciences Ltd.
He previously worked at Astellas Pharma US, Inc. for 12 years, where he held the position of Senior Vice President-Health Systems.
Stewart holds a Master's in Business Administration from Bellevue University and an undergraduate degree from Wichita State University.
Aktive Positionen von Kenton Stewart
| Unternehmen | Position | Beginn |
|---|---|---|
| UROVANT SCIENCES LTD. | Sales & Marketing | 02.06.2020 |
Ehemalige bekannte Positionen von Kenton Stewart
| Unternehmen | Position | Ende |
|---|---|---|
Astellas Pharma US, Inc.
 Astellas Pharma US, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma US, Inc. manufactures pharmaceutical products. It offers cardiology, dermatology, immunology, infectious diseases, and urology. The firm was founded in 2005 and is headquartered in Northbrook, IL. | Corporate Officer/Principal | 01.01.2018 |
Ausbildung von Kenton Stewart
| Bellevue University | Masters Business Admin |
| Wichita State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Astellas Pharma US, Inc.
Astellas Pharma US, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma US, Inc. manufactures pharmaceutical products. It offers cardiology, dermatology, immunology, infectious diseases, and urology. The firm was founded in 2005 and is headquartered in Northbrook, IL. | Health Technology |
Urovant Sciences Ltd.
 Urovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
